Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children

S. Jayasinghe, C. Chiu, R. Menzies, Deborah Lehmann, H. Cook, C. Giele, V. Krause, P. Mcintyre

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

© 2015 Elsevier Ltd. Background: High incidence and serotype diversity of invasive pneumococcal disease (IPD) in Indigenous children in remote Australia led to rapid introduction of 7-valent conjugate pneumococcal vaccine (7vPCV) at 2, 4 and 6 months in 2001, followed by 23-valent polysaccharide pneumococcal vaccine (23vPPV) in the second year of life. All other Australian children were offered 3 doses of 7vPCV without a booster from 2005. This study evaluated the impact of the unique pneumococcal vaccine schedule of 7vPCV followed by the 23vPPV booster among Indigenous Australian children. Methods: Changes in IPD incidence derived from population-based passive laboratory surveillance in Indigenous children
Original languageEnglish
Pages (from-to)6666-6674
JournalVaccine
Volume33
Issue number48
DOIs
Publication statusPublished - 2015

Fingerprint Dive into the research topics of 'Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children'. Together they form a unique fingerprint.

Cite this